Zai Lab Limited Unsponsored ADR’s (NASDAQ:ZLAB) quiet period is set to end on Monday, October 30th. Zai Lab Limited Unsponsored ADR had issued 8,333,333 shares in its initial public offering on September 20th. The total size of the offering was $149,999,994 based on an initial share price of $18.00. During Zai Lab Limited Unsponsored ADR’s quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

ZLAB has been the subject of a number of research reports. J P Morgan Chase & Co initiated coverage on Zai Lab Limited Unsponsored ADR in a report on Monday, October 16th. They set a “neutral” rating and a $32.00 price objective for the company. Citigroup Inc. initiated coverage on Zai Lab Limited Unsponsored ADR in a report on Monday, October 16th. They set a “buy” rating for the company. Finally, Leerink Swann initiated coverage on Zai Lab Limited Unsponsored ADR in a report on Monday, October 16th. They set an “outperform” rating and a $42.00 price objective for the company.

COPYRIGHT VIOLATION WARNING: “Zai Lab Limited Unsponsored ADR’s Quiet Period To End on October 30th (NASDAQ:ZLAB)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/23/zai-lab-limited-unsponsored-adrs-quiet-period-to-end-on-october-30th-nasdaqzlab.html.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) opened at 28.24 on Monday. The company’s 50 day moving average price is $29.07 and its 200-day moving average price is $29.07. The company’s market capitalization is $1.39 billion. Zai Lab Limited Unsponsored ADR has a 12-month low of $23.80 and a 12-month high of $35.74.

About Zai Lab Limited Unsponsored ADR

Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.

Receive News & Ratings for Zai Lab Limited Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab Limited Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.